BRANFORD, Connecticut., November 12, 2021 / PRNewswire / – IsoPlexis (NASDAQ: ISO), the leader in functional single-cell proteomics, today announced the appointment of two new senior positions within the company. Michelle reid, Ph.D. joins IsoPlexis as Vice President of Service and Support, and Antoine Catalano joined as senior vice president of operations. With these appointments, IsoPlexis continues to strengthen its operations and product support teams, delivering high-need proteomics products with highly customer-centric support.
Ms. Reid comes to IsoPlexis with over 20 years of experience leading and developing customer experience teams for regulated and unregulated molecular products and a PhD in Molecular Biology from LaTrobe University in Australia. Previously, she was Senior Director of Customer Service and Support at PGDx, where she built the Customer Experience teams from scratch. She has also played a key role in the growth and development of the customer support team at QIAGEN, a global leader in sampling and analysis technologies for molecular diagnostics and life science research.
Prior to joining IsoPlexis, Mr. Catalano spent 11 years as Senior Director of Operations at PerkinElmer, Inc., a Massachusettsone-stop solution provider for the diagnostics, life science, food and application markets. He was also Senior Director of Manufacturing Operations at VisEn Medical Inc. from 2001 until its acquisition by PerkinElmer in 2010. Mr. Catalano has a background as a Manufacturing Scientist and Engineer and an MS in Chemistry from Brandeis University.
“We are delighted that Michelle and Anthony are joining our team at IsoPlexis,” said Sean Mackay, CEO of IsoPlexis. “As we move into the next phase of our growth, our new hires will help us continue our operational excellence and bring significant innovations to the market. Their vast experience will help us continue our global expansion and customer focus around the world. “
IsoPlexis opens a new era of functional proteomics. By identifying for the first time our most proteomically active single cells (or ‘superhero cells’), IsoPlexis enables researchers to connect more directly to biology in vivo and to develop more precise and personalized therapies. . IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and many others. The IsoPlexis platform is used by researchers around the world, including those from the world’s 15 largest pharmaceutical companies and most of the major US cancer centers.
Caution regarding forward-looking statements
Certain statements contained in this press release are forward-looking statements that are subject to risks and uncertainties that could cause results to differ materially from expectations. Important factors that could cause actual results to differ materially include: the rate of adoption of the Company’s technology by its clients and potential clients as well as the risk factors set out in the Risk Factors section of the Company’s prospectus filed with the SEC. These forward-looking statements are not guarantees of future performance and are only valid as of the date hereof, and, except as required by law, IsoPlexis disclaims any obligation to update these forward-looking statements to reflect events or future circumstances.